Selank studies at Sigma A Peptides

The Selank research compound

Selank is a synthetic peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its parent is tuftsin, an immune-regulatory fragment of immunoglobulin G; the added Pro-Gly-Pro tail slows enzymatic breakdown. The 2018 molecular review describes this tuftsin-derived compound and its proposed anxiolytic biology. TP-7 and tuftsin analogue Selank are other names for it in the literature.

I trust Selank's individual experiments more readily than its broad reputation. A molecule can affect several systems and still leave its practical effects in people uncertain. Selank's record gives the reader GABA-related binding, gene-expression work, enkephalin degradation, immune measurements and a small human anxiety study to consider separately.

Selank mechanism of action

The rat brain membrane binding experiments discussed in the 2018 review describe positive allosteric modulation of GABA receptor binding: Selank changes how GABA binds at the receptor. The reported effects depended on concentration and receptor subtype, and Selank could block the modulating activity of diazepam and olanzapine. That is more intricate than the easy shorthand of a mild sedative.

Another route appears in the human-plasma enzyme assay. Selank inhibited enzymes that break down enkephalins, with an IC50 of approximately 15 micromolar. This was an in vitro result. Preserving endogenous opioid peptides is a proposed explanation for anxiety effects; the assay itself measured enzyme activity.

In rat frontal cortex, Selank altered expression of genes involved in GABAergic neurotransmission. Significant changes involved 45 genes at 1 hour and 22 at 3 hours, and the pattern correlated positively with changes produced by GABA. For me, this gives the binding work a useful companion, with a different measurement and its own timing.

Selank studies: behavior and symptoms

The 2017 chronic-stress experiment in rats found that Selank with diazepam reduced anxiety-related behavior more effectively than either alone, bringing behavior toward pre-stress levels. The combination is interesting precisely because these compounds can interact. It leaves human combination safety unresolved.

The 2008 Russian clinical study in generalized anxiety disorder and neurasthenia reported anxiolytic and mildly activating effects comparable to its benzodiazepine comparator, without the reported sedation, cognitive impairment or withdrawal. This is the human anxiety trial in this site's source list. Its encouraging short-term tolerability deserves attention alongside the limited replication and regional concentration of the evidence.

Other measurements broaden the biological picture: BDNF expression increased in the rat hippocampus, while in vitro and in vivo assays involving patients with anxiety-asthenic disorders showed changes in Th1/Th2 balance in patient serum and IL-6 expression in peripheral blood. I resist adding those to an imaginary total for effectiveness. They identify different biological questions for further work.

Selank HPLC and sample quality

A search for Selank HPLC raises the question of the material itself. I have no batch analysis to offer here. The studies describe their research findings; they cannot certify the identity, purity or sterility of a different sample of research-labelled Selank.

Supplier-dependent purity and uncertain identity are cautions in the research record. So are short human follow-up and poorly characterized interactions across GABAergic, opioid and immune systems. For a reader arriving through Selank HPLC, my answer stops at that boundary: the papers below offer pharmacology and a limited clinical record, with no assurance about a particular sample.

Reported effects, cautions & safety

The following community reports are compiled from nootropic forums, peptide-user guides, and biohacker blogs. They are anecdotal, not clinical evidence, and are presented separately from the cited research findings above.

What users commonly report (anecdotal):

• Calm without sedation — The most consistent account is anxiety softening without the heavy fog of benzodiazepines or the emotional flatness of SSRIs. Users describe the volume on anxious thoughts turning down while the mind stays clear.
• Reduced situational anxiety — Many users take it before high-pressure events — presentations, exams, difficult conversations — and report markedly fewer nerves and lower anticipatory build-up.
• Fast onset intranasally — A shift is commonly noticed within 20 to 40 minutes via the intranasal route, making it useful as an as-needed tool before stressful events.
• Calm but sharp focus — A "calm but sharp" state is frequently described, with easier concentration once anxious mental chatter quiets.
• Mood lift over time — Many report a gradual mood lift and a more even-keeled baseline that builds over one to two weeks of regular use.
• Short per-dose duration — A very common complaint is that the noticeable effect lasts only a few hours. Non-response is also a real and commonly voiced part of the picture — some people report finishing a full vial and noticing nothing.
• Nasal irritation — Mild nasal dryness, burning, or stinging is one of the most commonly mentioned downsides with the intranasal route.

Cited cautions from the literature:

• Unregulated sourcing. Research-labelled Selank sold outside Russia has no guaranteed identity, purity, or sterility. Purity varies by supplier, and impurities carry risks unrelated to the peptide's studied pharmacology.
• Long-term human safety is not established. Human data are limited to small Russian studies over short courses. Short, single-region trials cannot speak to chronic use over months or years ^[6].
• Interaction unknowns. Selank touches GABAergic, opioid, monoaminergic, and immune systems. The potential for additive or unpredictable interactions with medications acting on those same systems is real and essentially unstudied in people ^{[1][2][3][5][7]}.
• Immune-signaling activity. As a tuftsin analog, Selank shifts cytokine balance. Downstream consequences in people with autoimmune conditions or immune-modulating medications are not characterized ^[5].
• Self-treating anxiety is not a substitute for professional care. Anxiety that is persistent or impairing has established evidence-based treatments; an unapproved research peptide is not equivalent ^[6].
• Not FDA-approved. Regulatory registration exists essentially only in Russia. In the US, research-labelled Selank remains on sale for laboratory use and is not intended for human consumption ^[6]; prescribing belongs to a separate clinical assessment.

A closing note on where the supervised version of this sits. Every anecdote above belongs to someone who chose their own protocol, with no one screening for the interaction unknowns just listed. The blended medication Semax/Selank has a prescribing route at Promise Peptides (mypromise.com), where its product requires an individual prescription. Each U.S. patient's history goes to a licensed U.S. clinician, who can decline to prescribe; the patient's state and the treatment shape the options. The compounded product has no FDA approval, and supervision does not expand the evidence beyond a single Russian trial and a largely preclinical record ^[6].

Clinical replication

For anxiety relief, my strongest test would be a larger, well-controlled human study with longer follow-up. That is a judgment about the present gap. The small clinical trial offers a reason to investigate further, while the rat combination study gives an equally concrete reason to take interaction questions seriously.

Selank has no FDA or EMA approval. Research-labelled material is intended for laboratory work; U.S. compounded prescribing requires a clinician to assess the individual, and compounded medicines lack FDA approval. The comparison with Semax is useful for understanding the different experiments, and supplies no basis for choosing a treatment.